Intermittent chemotherapy in metastatic androgen-independent prostate cancer

被引：0
作者：
T M Beer
M Garzotto
W D Henner
K M Eilers
E M Wersinger
机构：
[1] Oregon Health & Science University,Division of Hematology and Medical Oncology, Department of Medicine
[2] Oregon Health & Science University and Portland VA Medical Center,Division of Urology
来源：
British Journal of Cancer | 2003年 / 89卷
关键词：
docetaxel; calcitriol; vitamin D; prostate cancer; chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) <4 ng ml−1. Chemotherapy was suspended until a rise in PSA⩾50% and 1 ng ml−1. The median duration of treatment holiday was 20 weeks (13–43+weeks) and all patients retained sensitivity to re-treatment. Chemotherapy holiday was associated with an improvement of fatigue (P=0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study.
引用
收藏
页码：968 / 970
页数：2
相关论文
共 104 条
[1]  
Aaronson NK(1993)The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 365-376
[2]  
Ahmedzai S(2001)Weekly high-dose calcitriol and docetaxel in advanced prostate cancer Semin Oncol 28 49-55
[3]  
Bergman B(1999)Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 3461-3467
[4]  
Bullinger M(2002)Chemotherapy for prostate cancer Urology 60 94-100
[5]  
Cull A(1995)Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report Urology 45 839-844
[6]  
Duez NJ(1996)Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study Urology 48 800-804
[7]  
Filiberti A(1999)Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study J Clin Oncol 17 2506-2513
[8]  
Flechtner H(1998)Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 139-144
[9]  
Fleishman SB(1999)Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone J Clin Oncol 17 1654-1663
[10]  
de Haes JC(1994)Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer Qual Life Res 3 353-364
12345678910